Asaf Cohen, n/a

CMC Director

Poster(s):

• (625) Manufacturing and Device Development for SPL84-23-1, an Inhaled Antisense Oligonucleotide, Supporting a First-in-Human Clinical Study in CF Patients Carrying the 3849+10kb C-to-T mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET